Bavisant

Bavisant
Clinical data
Other namesBEN-2001; BEN2001; JNJ-1074; JNJ1074; JNJ-31001074; JNJ31001074
Routes of
administration		Oral
Drug classHistamine H3 receptor receptor antagonist; Wakefulness-promoting agent
ATC code
  • None
Pharmacokinetic data
Elimination half-life14–22 hours
Identifiers
  • (4-cyclopropylpiperazin-1-yl)-[4-(morpholin-4-ylmethyl)phenyl]methanone
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC19H27N3O2
Molar mass329.444 g·mol−1
3D model (JSmol)
  • C1CC1N2CCN(CC2)C(=O)C3=CC=C(C=C3)CN4CCOCC4
  • InChI=1S/C19H27N3O2/c23-19(22-9-7-21(8-10-22)18-5-6-18)17-3-1-16(2-4-17)15-20-11-13-24-14-12-20/h1-4,18H,5-15H2
  • Key:BGBVSGSIXIIREO-UHFFFAOYSA-N

Bavisant (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code names BEN-2001 and JNJ-31001074) is a histamine H3 receptor receptor antagonist which was under development for the treatment of narcolepsy and attention deficit hyperactivity disorder (ADHD) but was never marketed. It is taken orally.

The drug is potent and highly selective for the histamine H3 receptor (Ki = 5.4 nM). Bavisant produces wakefulness-promoting effects in animals and humans, but can also cause insomnia. Its elimination half-life is 14 to 22 hours while its effective half-life is 13 to 20 hours.

Bavisant was under development by BenevolentAI and Johnson & Johnson. It reached phase 2 clinical trials for both narcolepsy and ADHD prior to the discontinuation of its development in 2022. The drug was not effective for the treatment of ADHD in a large clinical trial. Besides the preceding indications, it was also studied for the treatment of alcoholism. In 2026, bavisant was identified as a potential therapeutic agent for the treatment of multiple sclerosis.

See also

References

  1. 1 2 3 4 5 "BenevolentAI/Johnson & Johnson". AdisInsight. 5 November 2023. Retrieved 21 May 2026.
  2. 1 2 3 4 5 6 7 Sadek B, Łażewska D, Hagenow S, Kieć-Kononowicz K, Stark H (2016). "Histamine H3R Antagonists: From Scaffold Hopping to Clinical Candidates". Histamine Receptors. The Receptors. Vol. 28. Cham: Springer International Publishing. pp. 109–155. doi:10.1007/978-3-319-40308-3_5. ISBN 978-3-319-40306-9.
  3. 1 2 3 Vaidyanathan S, Kramer M, Berwaerts J, Pandina G, Li LY (2012). "Pharmacokinetics And Safety Of Bavisant (JNJ-31001074) After Single And Multiple Doses In Healthy Subjects: 1386236". Clinical Pharmacology in Drug Development. 1 (4): 199.
  4. 1 2 Kuhne S, Wijtmans M, Lim HD, Leurs R, de Esch IJ (December 2011). "Several down, a few to go: histamine H3 receptor ligands making the final push towards the market?". Expert Opinion on Investigational Drugs. 20 (12): 1629–1648. doi:10.1517/13543784.2011.625010. PMID 21992603.
  5. 1 2 3 4 5 Weisler RH, Pandina GJ, Daly EJ, Cooper K, Gassmann-Mayer C (May 2012). "Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder". CNS Drugs. 26 (5): 421–434. doi:10.2165/11631990-000000000-00000. PMID 22519922.
  6. ↑ Gacem N, Bezukladova S, Windener F, Karam T, Ottoboni L, Brambilla E, et al. (January 2026). "In silico screening and preclinical validation identify bavisant as a therapeutic candidate for multiple sclerosis". Science Translational Medicine. 18 (833) eads0633. doi:10.1126/scitranslmed.ads0633. PMID 41564155.